Your patients with new MET amplification after #NSCLC has progressed on osimertinib may be eligible for Lung-MAP sub-study SWOG Cancer Research Network S1900G. MET amplification found by tissue assay at a CLIA-certified lab can be used. SWOG.org/clinical-trial… #lungcancer

S1900K, Lung-MAP's newest sub-study, was activated in December. For patients with MET exon 14 skipping #NSCLC. Hypothesis: resistance to MET inhibition in these patients is due to VEGFR2 signaling. Tests adding ramucirumab to MET inhibitor tepotinib. clinicaltrials.gov/study/NCT06031…

Basket trials. Umbrella trials. Platform trials. What's the difference? Here's a clear explanation from Andrew Ciupek of GO2 for Lung Cancer: go2.org/blog/new-clini…. Lung-MAP is an umbrella trial in #NSCLC #lungcancer. Patients are matched to targeted therapy by #biomarker testing.

#Lung MAP. Umbrella master protocol driven by public-private partnership. Over 4,000 patients enrolled. 15 trials completed. Nothing else like it! Lung-MAP Hossein Borghaei, DO Karen Reckamp, MD, MS Jhanelle Gray MD GO2 for Lung Cancer

#Lung MAP retreat at FNIH. NCI, FDA NCTN and investigators all here. Strategic planning ongoing. Here with friend & colleague Roy Herbst Lung-MAP NCI CTEP Clinical Research SWOG Cancer Research Network FDA Oncology Hossein Borghaei, DO Karen Reckamp, MD, MS

The Lung-MAP precision medicine trial in non-small cell lung cancer is approaching its 10-year anniversary. A decade of bringing the right treatment to the right patient at the right time. The master protocol's next evolution is coming soon: Lung-MAP 3.0! lung-map.org

The Lung-MAP trial is built on a unique public-private partnership including National Cancer Institute Foundation for the National Institutes of Health Friends of Cancer Research SWOG Cancer Research Network #NCTNPartnership benefits: - Shared costs & risks of testing therapies - Drug combination collaborations between companies - Large network shortens timeframes

At #ASCO24, Dr. John Wrangle presents results of Lung-MAP sub-study S1800D, which tested N-803 + pembro vs SOC in patients w adv #NSCLC. Sat, Jun 1, 9am-12pm CT, Hall A Session: Dev Therapeutics-Immunotherapy meetings.asco.org/abstracts-pres… SWOG Cancer Research Network NCI CTEP Clinical Research Friends of Cancer Research Foundation for the National Institutes of Health

The S1900K Lung-MAP sub-study is enrolling patients with MET exon 14 skipping #NSCLC. Hypothesis: resistance to MET inhibition in these patients is due to VEGFR2 signaling. Tests adding ramucirumab to MET inhibitor tepotinib. clinicaltrials.gov/study/NCT06031… Foundation for the National Institutes of Health Friends of Cancer Research SWOG Cancer Research Network

The Lung-MAP community mourns the loss of Ivy Elkins, whose insights have helped the Lung-MAP trial better meet the needs of patients w #NSCLC, incl. at our Aug 2023 webinar "Advocating, Accelerating, & Amplifying Lung Cancer Discovery" youtube.com/watch?v=Mx68mL…. Thank you, Ivy.

A Closer Look at the Innovative Pragmatica-Lung Trial SWOG Cancer Research Network S2302 chair Karen Reckamp, MD, MS interviewed on streamlined phase 3 trial in #NSCLC w broader eligibility & lower site burden. Rewriting how we do oncology #ClinicalTrials. Lung-MAP NCI CTEP Clinical Research medpagetoday.com/meetingcoverag…

The Lung-MAP master protocol has screened more than 5,000 patients with advanced #NSCLC. Data from these patients are driving #research to further our understanding of common #lungcancer mutations and to discover future treatment targets. Learn more: lung-map.org

Just out in JTO: Lung-MAP Next Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG Cancer Research Network S1400) NGS data for 1,672 patients enrolled to Lung-MAP is a rich resource for biomarker discovery. National Cancer Institute Friends of Cancer Research Foundation for the National Institutes of Health Mike Wu jto.org/article/S1556-…

There is growing interest in using pragmatic clinical trials (PCTs) bridge the gap between research and practice in oncology, more closely resembling real-world care. Results from a recent Lung-MAP study supported the development of Pragmatica-Lung. aacrjournals.org/clincancerres/…

The Lung-MAP precision medicine trial in non-small cell lung cancer has turned 10 -- a decade of bringing the right treatment to the right patient at the right time. The master protocol's next evolution is coming soon: Lung-MAP 3.0! Stay tuned. lung-map.org

There is growing interest in using PCTs to bridge the gap between research and practice in oncology, more closely resembling rw-care. Results from a study conducted as part of Lung-MAP supported the development of a new pragmatic study (Pragmatica-Lung) aacrjournals.org/clincancerres/…

S1900K is a new Lung-MAP sub-study that tests combining ramucirumab and tepotinib for non-small cell #lungcancer that has a SWOG.org/S1900K. Or call 1-800-4-CANCER. #lcsm #nsclc @GO2Foundation

#Lungcancer study S1900K asks if adding ramucirumab to tepotinib treatment can lessen the side effect of swelling in the arms and legs. It’s for people with cancer that has a METex14-skipping gene change. Learn more at SWOG.org/S1900K. Or call 1-800-4-CANCER. #lcsm #nsclc

New Friends perspective in ESMO - Eur. Oncology RWD & Digital Health discusses the potential of incorporating pragmatic elements in oncology clinical trials. #PragmaticTrials are a promising way to achieve more efficient, relevant, & patient-centered drug development. bit.ly/4cAkUOz

The Lung-MAP precision medicine trial’s S1900K sub-study randomizes patients w MET exon 14 skipping-positive advanced non-small cell #lungcancer to tepotinib w/wo ramucirumab. PI: Paul K. Paik, MD BenWellington. An ECOG-ACRIN Cancer Research Group sub-study. SWOG.org/clinical-trial… #NSCLC #lcsm